Bayer’s Koenen: Decentralized Trials For Pivotal Studies Not 'Black Or White Scenario'

A cross-section of biopharma experts including senior executives of Bayer, Boehringer Ingelheim and Accenture and US FDA Director at the India Office deliberate digitization and evolving trends in clinical research, including the potential of decentralized trials and metadata-driven automation.